IL1B and inflammatory bowel disease: All therapeutic interventions demonstrated significant downregulation of key pro-inflammatory mediators (IL-1β, IL-6, INF-γ, TNF-α) compared to untreated IBD controls, with the LU + QR combinatorial treatment and 5-ASA monotherapy achieving superior anti-inflammatory efficacy.